FindTrial
Sign In

Efficacy of Human Gut microbiota-derived consortium complex for irritable bowel syndrome patients

Efficacy of Human Gut microbiota-derived consortium complex for irritable bowel syndrome patients: A open-label, prospective, observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007709
Enrollment
44
Registered
2022-09-16
Start date
2022-09-16
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Hallym University Medical Center-Kangnam
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients (19 years or older) who met the Rome IV criteria for the diagnosis of IBS were eligible to participate.

Exclusion criteria

Exclusion criteria: The exclusion criteria were previous abdominal surgery except appendectomy and Caesarian section, inflammatory bowel syndrome, and concurrent severe illness (cancer, cardiovascular or pulmonary disease). In addition, patients who had used antipsychotics, antibiotics, and probiotics within the two weeks were also excluded.

Design outcomes

Primary

MeasureTime frame
Change of IBS Symptom Severity assessed with the IBS Severity Scoring System (50 points or more decrease) : Assessed using IBS SSS Questionnaire—

Secondary

MeasureTime frame
Change of abdominal pain Severity assessed with the IBS Severity scoring System (10 points or more decrease) : Assessed using IBS SSS Questionnaire;Change of Irritable Bowel Syndrome Quality of Life Score (10 points or more decrease) : Assessed using IBS- QOL Questionnaire—

Countries

Korea, Republic of

Contacts

Public ContactChang Kyo Oh

Hallym University Medical Center-Kangnam

ckdryekd@gmail.com+82-2-829-5120

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026